Let’s Geek Out: 3 Reasons You Should Care About The DreaMed and Medtronic Partnership

Closing The Diabetes Loop - DreaMed, Medtronic

A diabetes development hits the news every five minutes. Our job at the DDG, is to showcase to you which of these really matter. We think this DreaMed and Medtronic partnership matters. Why? We’ll get there, but first, let’s define the agreement.

Basically, Medtronic bought DreaMed’s CGM algorithm technology. Here’s a excerpt from the previously linked article by news-medical.net, describing the algorithm:

DreaMed Diabetes’s CE approved GlucoSitter™, which is based on the MD-Logic Artificial Pancreas algorithm, is a fully-automated, artificial-pancreas system for controlling glucose levels. The system links the glucose sensor with the insulin pump through computerized control algorithms. It uses data of glucose levels from a continuous glucose sensor, analyzes them and directs the insulin pump to deliver the correct dose of insulin that should be released to the body in order to maintain balanced blood glucose. In effect, the software continuously monitors glucose levels, and defines precisely when and how to adjust insulin levels.

Now, let’s talk importance: Continue reading

Tuesday Topic: Putting Stem Cells In My Body?

thought bubble

Viacyte, a San Diego based regenerative health/drug company, set off ripples of hope and relief in the diabetes community.  We’ve been dreaming of drinking coffee without blood sugar spikes, running an hour without being low for the next hour, and not having to smother my pump’s low battery alarm during meetings.

Here’s a quick review of the announcement—Viacyte is moving forward with an application, to the FDA, to initiate Phase I/II clinical trials in Type 1 diabetes patients.  They’re testing safety and efficacy of an implantable device that secretes insulin through enclosed stem cells, turned to pancreatic beta cells, effectively removing the need for diabetics to take insulin.  Found on Viacyte’s website, here’s their grandiose take on the product’s possibilities:

“In short, ViaCyte’s VC-01 combination product has the potential to transform the way diabetes care is managed. The product could be a virtual cure for type 1 diabetes and an important new therapy for insulin-requiring type 2 diabetes.”

VC-01-cross-section-5 Continue reading